Taking into account the limited guidance that is available to prescribing physicians who are concerned about the value of some/all drugs in a current regimen, PRIUM created TaperRx to provide that guidance. The primary deliverable is a “roadmap” that outlines which drug/drug classification should be tapered first, what the evidence says about how to taper, and identify milestones or thresholds that need to be met before making other pharmacological changes. Clinical details and references beyond the “roadmap” are also provided to answer questions that prescribing physicians and/or patients may have, along with supporting narrative on how to address the psychosocial component.
TaperRx was developed, and is continually maintained, by a combination of PharmD’s (who understand pharmacology) and MD’s (who understand treatment), and that maintenance is designed to ensure new evidence is incorporated so that the “roadmap” is always relevant and up-to-date. This “roadmap” obviously does not supplant the need for physician expertise and patient motivation. However, by using TaperRx, the physician, patient, and payer can have confidence in knowing they are leveraging the best information possible to affect change.